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Abstract 
The serotonergic system has close interactions with the dopaminergic system and is strongly implicated 
in the pathophysiological mechanisms and therapeutic paradigms of Parkinson’s disease (PD). This study 
aims to investigate regional changes in 5-hydroxytryptamine (5-HT) 2A receptors in the rat brain 3 weeks 
after unilateral medial forebrain bundle lesion by 6-hydroxydopamine (6-OHDA). 5-HT 2A receptor 
distributions and alterations in the postmortem rat brain were detected by [3H]ketanserin-binding 
autoradiography. In the 6-OHDA-induced Parkinson’s rat model, nigrostriatal dopaminergic neuron loss 
significantly mediated the decreased [3H]ketanserin binding, predominantly in the agranular insular cortex 
(17.3%, P 5 0.03), cingulate cortex (18.2%, P < 0.001), prefrontal cortex (8%, P 5 0.043), primary 
somatosensory cortex (17.7%, P 5 0.002), and caudate putamen (14.5%, P 5 0.02) compared to controls 
while a profound reduction of tyrosine hydroxylase (TH) immunostaining in the striatum was also 
observed. Alterations in [3H]ketanserin binding in the examined brain areas may represent the specific 
regions that mediate cognitive dysfunctions via the serotonin system. The downregulation of 5-HT2A 
receptor binding in this study also provides indirect evidence for plasticity in the serotonergic system in 
the rat brains. This study contributes to a better understanding of the critical roles of 5-HT2A receptors in 
treating neurodegenerative disorders and implicates 5-HT2A receptors as a novel therapeutic target in the 
treatment of PD. 
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The serotonergic system has close interactions with the dopaminergic system and is 
strongly implicated in the pathophysiological mechanisms and therapeutic paradigms 
of Parkinson’s disease. This study aims to investigate regional changes in 5-
hydroxytryptamine (5-HT) 2A receptors in the rat brain three weeks after unilateral 
medial forebrain bundle lesion by 6-hydroxydopamine. 5-hydroxytryptamine (5-HT) 
2A receptor distributions and alterations in the post-mortem rat brain were detected by 
[3H]ketanserin binding autoradiography. In the 6-hydroxydopamine-induced 
Parkinson’s rat model, nigrostriatal dopaminergic neuron loss significantly mediated 
the decreased [3H]ketanserin binding, predominantly in the agranular insular cortex 
(17.3%, p = 0.03), cingulate cortex (18.2%, p< 0.001), prefrontal cortex (8%, p= 
0.043), primary somatosensory cortex (17.7%, p= 0.002) and caudate putamen 
(14.5%, p= 0.02) compared to controls while a profound reduction of tyrosine 
hydroxylase (TH) immunostaining in the striatum was also observed. Alterations in 
[3H]ketanserin binding in the examined brain areas may represent the specific regions 
that mediate cognitive dysfunctions via the serotonin system. The down-regulation of 
5-HT2A receptor binding in the present study also provides indirect evidence for 
plasticity in the serotonergic system in the rat brains. The present study contributes to 
a better understanding of the critical roles of 5-HT2A receptors in treating 
neurodegenerative disorders, and implicates 5-HT2A receptors as a novel therapeutic 
target in the treatment of Parkinson’s disease.  
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5-hydroxytryptamine (5-HT) receptors (with main types from 1 to 7 for a total of 14 
different subtypes) have been widely identified in the central nervous system. As the 
G protein-coupled receptors (GPCR), 5-HT receptors are involved in various signal 
transduction pathways, including inhibition or activation of adenylyl cyclise, 
phosphatidylinositol-specific phospholipase C or Janus kinase/signal transducers and 
activators of the transcription pathway, and regulation of extracellular signal-
regulated mitogen-activated protein kinase, proliferation related pathways, or the 
extracellular signal-regulated kinase (Raymond, 2001).  
                 It is well documented that there is a close interaction between brain 
serotonergic and monoamine dopaminergic systems (Alex, 2007). The dopaminergic 
disturbance in the brain may lead to serotonergic changes. In vivo microdialysis 
studies showed that local infusion of the D2 receptor antagonist raclopride 
significantly inhibited the tail pinch-induced serotonin increases in the prefrontal 
cortex and corpus striatum (Mendlin, 1999). Similar results also indicated that local 
administration of the nonselective dopamine receptor agonist apomorphine into the 
hippocampus increased 5-HT release in a concentration-dependent manner, and this 
increase was abolished by pre-treatment with the selective D2 receptor antagonist, S(–
)-sulphide (Matsumoto, 1996). Reciprocally, serotonin afferents are able to facilitate 
the release of dopamine.  It has been shown that dopamine release is induced in 
different brain regions following local cerebral application with serotonin (Parsons 
and Justice, 1993; West and Galloway, 1991).  
             In addition to the correlation between serotonin and dopamine transmission, 
there is tight functional interaction between these receptors. It has been shown that 5-
HT2A receptors are co-expressed with dopamine 1-5 receptors in different brain 
 4
regions, such as the substantia nigra pars compacta, striatum and cortex (Goldman-
Rakic, 1999). Immunohistochemistry with confocal microscopy showed that 5-HT2A 
receptors were co-localised with tyrosine hydroxylase and were expressed on 
dopaminergic neurons within the A10 dopamine subnuclei (Nocjar, 2002). Alterations 
of 5-HT receptors in the brain are closely associated with the dopaminergic system. 
One study by Pehek showed that intracortical infusion of the 5-HT2A receptor 
antagonist M100907 profoundly attenuated dopamine release induced by systemic 
administration of the 5-HT agonist, suggesting that stimulation of cortical 5-HT2A 
receptors increased dopamine release from the mesocortical system (Pehek, 2006). 
Similar dopamine modulation was also observed by systemic or local administration 
of the 5-HT2C receptor agonist mCPP or SB 206553 (Alex, 2005).  
                   Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder following Alzheimer’s disease (AD) with the typical disturbance of the 
central dopaminergic system (Wang and Ying, 2009) and imbalances in some non-
dopaminergic systems, including the serotonergic system (Scholtissen, 2006a; 
Scholtissen, 2006b; Zgaljardic, 2004; Zhang, 2008). Considering the interactions 
between the dopaminergic and serotonin receptors are well documented (Alex, 2007), 
here we explore whether 5-HT2A receptors in the different rat brain regions are also 
changed in 6-hydroxydopamine (6-OHDA) lesioned Parkinsonian rats. To the best of 
our knowledge, the 5-HT2A receptor binding site in adult rat brain has not been 
systematically investigated. To address this issue, we used [3H]ketanserin binding 
autoradiography, a serotonin antagonist with high affinity for the 5-HT2A receptors to 
study serotonin responses following 6-OHDA lesion treatment across a wide range of 
brain structures.  
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Materials & Methods 
Animals and drug treatments 
Sixteen male Sprague-Dawley rats (230-250g) were obtained from the 
Animal Resources Centre (Perth, Western Australia, Australia) and housed 
individually in environmentally controlled conditions (22°C, 12 h light-dark cycle 
with light cycle from 0600 to 1800 h and dark cycle from 1800 to 0600 h) with ad 
libitum access to standard laboratory chow and water. Rats were allowed 1 week to 
adapt to their new environment before experiments began. They were randomized 
with eight rats for controls receiving vehicle and eight rats for 6-hydroxydopamine (6-
OHDA)-induced Parkinsonian treatment (One rat from the latter group died during 
surgery). Three weeks after 6-OHDA lesion, rats from each group were sacrificed to 
examine 5-HT2A receptor binding. The reasons for the timepoint of 3-week 
observation are that some studies have indicated that 3 weeks after 6-OHDA injection, 
85% nigral dopaminergic neurons lost in SNc (Anastasia, 2007), whilst we also would 
like to explore the short-term effects with 6-OHDA lesion. This study has been 
approved by the University of Wollongong Animal Ethics Committee and all animal 
experiments were conducted in compliance with the National Institute of Health 
Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) 
revised 1996 guidelines and National Health and Medical Research Council 
(NHMRC) Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes (2004).  
6-OHDA lesioned Parkinsonian rats 
 
                  6-OHDA lesioned Parkinsonian rats were prepared as described in our 
previous works (Wang, 2005). Briefly, male Sprague–Dawley rats (weight 230–250 
g) were anesthetized with 75 mg/kg ketamine and 10 mg/kg xylazine (Troy 
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laboratories Pty, Ltd., Australia). Lesions were made by injecting 6-OHDA 
unilaterally (4 μl of 8 μg/μl in normal saline containing 0.2 mg/ml ascorbic acid, 
Sigma-Aldrich, St. Louis, MO; 0.8 μl/min) into the medial forebrain bundle (MFB) at 
the Bregma level AP −4.4 mm, ML −1.4 mm and DV −7.8 mm (Paxinos and Watson, 
1997; Wang, 2005).  The control group received the vehicle. All experiments were 
carried out in accordance with the guidelines set by the University of Wollongong, 
adapted from Howard-Jones (Howard-Jones, 1985).   
Histology and [3H]ketanserin binding autoradiography 
 
                Three weeks later, rats were sacrificed by rapid CO2 asphyxiation. In order 
to minimise the impact of circadian variation on binding density, the rats were 
sacrificed between 0700 and 0900 hours, and the brains were immediately removed 
and frozen in liquid nitrogen. Coronal brain sections (14um) were cut at -17oC with a 
cryotome (Clinicut cryostat; Bright Instruments), and thaw-mounted onto poly-L-
lysine coated microscope slides (Polysine™, Menzel GmbH & Co KG) (Wang and 
Huang, 2008). Consecutive sections were used for the detection of the 5-HT2A 
receptor binding site. Neuroanatomical structures were identified according to a 
standard rat brain atlas (Paxinos and Watson, 1997). [3H]ketanserin autoradiography 
was performed as described in our previous works (du Bois, 2006). In summary, 
binding of [3H]ketanserin (67.0Ci/mmol; PerkinElmer Life Sciences, Boston, MA, 
USA) to 5-HT2A receptors was measured by preincubating sections in 170 mM Tris–
HCl buffer (pH 7.4) for 15 min at room temperature (RT). Sections were incubated 
for 120 min at room temperature in buffer containing 2 nM [3H] ketanserin. Non-
specific binding was determined by the addition of 2 μM spiperone to a third of the 
sections. Sections were washed in 4 °C buffer (2×10 min), dipped in distilled water 
and dried.    
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Tyrosine hydroxylase immunohistochemistry staining                                                     
                 Tyrosine hydroxylase (TH) staining was performed as described in Yuan’s 
study (Yuan, 2005). Briefly, endogenous peroxidase was quenched with 0.3% H2O2 
(30 min). Then the sections were washed with distilled water (3 × 5 min) and placed 
in citrate buffer 0.1 M pH 5.8 (20 min at 60–80 °C). They were then washed in 
distilled water followed by PBS (5 min). Non-specific binding was blocked with 1.5% 
normal goat serum (Vectastain rabbit IgG ABC kit) (60 min). This was followed by 
application of TH primary antibody (rabbit polyclonal anti-tyrosine hydroxylase, 
Millipore Corporation, AB152) diluted to 1:500 in blocking solution and incubated 
overnight at 4 °C. After washing in PBS (3 × 5 min), the sections were incubated with 
a 1:200 dilution of the biotinylated anti-rabbit secondary antibody (Vectastain rabbit 
IgG ABC kit) for 60 min followed by washes with PBS (3 × 5 min). The horseradish 
peroxidase conjugate ABC (Vectastain rabbit IgG ABC kit) was applied for 60 min 
followed by PBS rinses (3 × 5 min). 3,3′-Diaminobenzidine (Vector Labs), mixed 
with distilled water, buffer pH 7.5, H2O2, and Nickel stock (DAB, Vector SK-4100), 
was applied until staining was optimal as determined by light microscopy. The 
sections were then washed with tap water, dehydrated, cleared with xylene and 
coverslipped using DPX mountant. After TH-staining, the image of the sections from 
the striatum were digitalized with a camera (Nikon D80, Nikon Japan), connected to 
an Olympus microscope and a computer. Density in the striatum was measured using 
the NIH ImageJ Analysis software.  
Quantification and Statistical Analysis 
               Quantification of binding sites was performed on a high-resolution Beta 
Imager (BioSpace, Paris, France) according to our previous study (Wang, 2008). In 
brief, sections were placed inside the detection chamber of the Beta Imager and 
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scanned for 3.5 h at a high-resolution setting. The levels of bound radioactivity in the 
brain sections were directly determined by counting the number of β-particles 
emerging from the tissue sections, which was followed by analysis of activities in the 
regions of interest using the Beta Vision Plus program (BioSpace). The radioligand 
binding signal was expressed in counts per minute per square millimetre (cpm/mm2) 
and a series of sections with known quantities of ligands were used as standards in all 
scans allowing the measurement of radioligand binding signals to be converted to 
nCi/mg tissue equivalents. The [3H] ketanserin binding density in various brain 
regions was quantified by measuring the average density of each region in three to 
five adjacent brain sections. Different brain regions were identified with reference to a 
standard rat brain atlas (Paxinos and Watson, 1997). Data were expressed as mean ± 
SEM. [3H] ketanserin binding densities for each brain region were analysed using a 
one-way ANOVA followed by independent t-test analysis using the SPSS 15.0 
program (Chicago, IL). p values of less than 0.05 were regarded as statistically 























               Specific [3H] ketanserin binding was observed in most brain regions 
examined, although there were regional variations in density (Fig 1). Nonspecific 
binding was observed to be less than 5% (Fig 1). The highest density of [3H] 
ketanserin binding was observed in the agranular insular cortex and prefrontal cortex. 
Moderate levels of [3H] ketanserin binding were observed in the cingulate cortex, the 
primary motor cortex, and some limbic regions including the nucleus accumbens and 
primary somatosensory cortex. Low levels of [3H] ketanserin binding were observed 
in the amygdala and caudate putamen.  In addition, we found that the [3H] ketanserin 
binding level is very low in the substantia nigral area and hardly to detect it. Our 
result is consistent with Du Bois study (du Bois, 2006).  
                
Effects of 6-OHDA lesion on [3H] ketanserin binding in different brain regions 
               The analysis revealed significant differences in [3H] ketanserin binding in all 
brain regions examined except Acb, Amy and M1 among 6-OHDA lesioned rat. 
Three weeks after 6-OHDA lesion, [3H] ketanserin binding was significantly lower in 
five of eight brain regions examined compared to the controls (Figs 2 and 3). 
Specifically, 6-OHDA lesion significantly decreased [3H] ketanserin binding density 
in the agranular insular cortex (17.3%, p= 0.03), the cingulate cortex (18.2%, p< 
0.001), the prefrontal cortex (8%, p= 0.043), S1 (17.7%, p= 0.002) and the caudate 
putamen (14.5%, p= 0.02) compared to the controls. However, compared to the 
controls, 6-OHDA lesion induced no significant changes in [3H] ketanserin binding in 
the nucleus accumbens (p= 0.138), the amygdala (p= 0.079) and the primary motor 
cortex (p= 0.061) (Fig 3).  
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Effects of 6-OHDA lesion on TH immunohistochemistry staining in the caudate 
putamen 
               In the Striatum:  Coronal section (Fig. 4) throughout the striatum indicating 
the extent of nigrostriatal denervation induced by injecting the neurotoxin 6-OHDA 
into the right MFB, as seen by tyrosine hydroxylase immunoreactivity. The right side 
of the photo (Fig. 4A) shows the dopamine-depleted striatum side characterized by a 
large absence of TH immunoreactive fibres. The density of TH-positive fibres was 
expressed as a mean percentage ± S.E.M relative to the intact side, in which the dense 
TH-immunoreactive fibres were found throughout the striatum. Compared to the 
controls, around 80% reduction in the density of TH-positive fibres in the striatum 
was observed in 6-OHDA induced PD rats (Student t-test: t=15.696, *** p< 0.001, 
Fig. 4C). The density of TH immunoreactive fibres in the striatum among the control 
group (Fig 4B) is the same as that of intact side of 6-OHDA induced PD rats.  
 
























               The present study was designed to investigate [3H] ketanserin binding 
density in 6-OHDA lesioned PD rats. [3H] ketanserin has a specific affinity for 5-
HT2A receptors and the [
3H] ketanserin binding densities directly reflect the 5-HT2A 
receptor levels and distributions in the rat brain following 6-OHDA lesion. Although 
there were regional variations in 5-HT2A receptor binding density, our finding 
suggests that the decrease in 5-HT2A receptors due to 6-OHDA lesion probably plays 
an important role in the progression of Parkinson’s disease.   
Our study shows that a significant down-regulation of [3H] ketanserin 
binding densities was observed three weeks among 6-OHDA lesioned PD rats, 
predominantly in the agranular insular cortex, the cingulate cortex, the primary 
somatosensory cortex, the caudate putamen and the prefrontal cortex. This suggests 
that 6-OHDA lesion may interfere with 5-HT2A receptor expression and may prevent 
[3H] ketanserin binding to the receptors, or enhance the receptor degradation and 
desensitization. In addition, the down-regulation of 5-HT2A receptor binding in the 
present study provides indirect evidence for the plasticity of the serotonergic systems 
in the rat brain. The down-regulation of 5-HT2A receptors in some mesocortical 
regions is linked to increased anxiety and impaired memory. It is expected that the 5-
HT2A receptors’ agonist like DOI may have important clinical implication in 
improving the cognitive deficits in PD.  
               Our study showed that three weeks after MFB lesion by 6-OHDA TH- 
immunostaining displayed a profound decreased in density of TH-positive fibres in 
the striatum (Fig 4), which indicated an obvious dopaminergic neuronal degeneration 
and complete nerve terminal denervation. This result is consistent with observations 
made by Yuan (Yuan, 2005). Destruction of the dopaminergic nigrostriatal pathway 
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due to MFB lesion in this study mediated an obvious down-regulation of 5-HT2A 
receptor binding, indicating that the loss of dopaminergic afferents induced decreased 
5-HT2A receptor expression in the striatum. This hypofunction of the 5-HT2A receptor 
could be due to 5-HT hypo-innervations or the reduced number of 5-HT terminals 
after 3-week MFB lesion. Interestingly, our result is different from Zhang’s study that 
indicated an increase in 5-HT2A receptor mRNA expression in the striatum (Zhang, 
2007). This discrepancy may result from the following reasons: 1) in our study, we 
injected in total 32 μg 6-OHDA into the right medial forebrain bundle but Zhang only 
injected 12.5 μg (thus, 2.56 times more 6-OHDA neurotoxin was   used in our study; 
2) we measured 5-HT2A receptor binding three weeks after MFB lesion and this 
showed one week earlier in comparison to Zhang’s study, and the turnover of 5-HT2A 
receptors did not occur during the short period of three weeks. In our study, the high 
dose of neurotoxin and shorter observed time following 6-OHDA MFB lesion leading 
to the down-regulation of 5-HT2A receptor binding in the striatum in stead of 
elevation suggests that during the early stage of Parkinson’s disease, dopaminergic 
denervation usually has a parallel influence on the expression of striatal 5-HT2A 
receptors. However, whether 5-HT2A receptors rebound in the striatum according to 
the prolonged timing course remains to be determined.   
                In addition to the down-regulation of 5-HT2A receptor expression in the 
striatum three weeks after MFB lesion, 5-HT2A receptor binding was also decreased in 
some mesocortical regions, such as the primary motor cortex, the cingulate cortex, the 
agranular insular cortex and the prefrontal cortex. It has been shown that the 
dopamine neurons in the mesocortical pathway project from the ventral tegmental 
area (VTA) and the medial substantia nigra pars compacta to the frontal lobe. 
Dopaminergic disruption in Parkinson’s disease not only affects the nigrostriatal tract 
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but also the mesocortical pathway (Jellinger, 2001). Since the brain serotonergic and 
monoamines dopaminergic systems have close interactions, Parkinson’s disease 
reflects abnormalities in the mesocortical pathways with the serotonergic system 
(Doder, 2003). The down-regulation of 5-HT2A receptor in examined mesocortical 
regions observed in this study may reflect 5-HT hypo-innervations following 6-
OHDA lesion since some studies have indicated that unilateral 6-OHDA lesion of the 
nigrostriatal dopaminergic system abolished increases in cortical-striatal serotonin 
output (Mendlin, 1999).   
.           Increasing evidence shows that interruptions to the frontostriatal circuitry 
will elicit disturbances in cognitive, emotional, and memory disturbances among 
people afflicted with Parkinson’s disease. Tamaru indicated that the dysfunction of 
the nigrostriatal dopaminergic system and cortical-basal ganglionic circuits 
connecting the frontal lobe and the basal ganglia obviously induced a series 
impairment of cognitive functions like memory, attention, and executive function in 
Parkinson’s patients (Tamaru, 1997). As one of the main 5-HT receptors, the 
dysfunction of 5-HT2A receptors are recognised for their important roles and 
implications in a number of cognitive and stress-related disorders (Huang, 2007). 
Weisstaub demonstrated that the global disruption of 5-HT2A receptor signalling in 
mice significantly reduced inhibition in conflict anxiety without affecting fear-
conditioned and depression related behaviours, indicating a specific role of cortical 5-
HT2A receptor function in the modulation of conflict anxiety (Weisstaub, 2006). A 
recent study by Anseloni showed that the reduced anxiety was associated with the 
increase in expression of 5-HT2A receptors in the rat brain (Anseloni, 2005). Since 5-
HT2A receptors localised in the mesocortical regions such as the prefrontal cortex 
have been found to be important modulators of executive functions including memory 
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and cognitive flexibility, evidences shows that the blockage or activation of 5-HT2A 
receptors can obviously attenuate (Williams, 2002) or enhance (Buhot, 1997) the 
learning and working memory. In our study, the decreased 5-HT2A receptors were 
observed in some mesocortical regions like the prefrontal cortex and the cingulate 
cortex (Fig. 3). Although the rat brain resembles the human brain to a certain degree, 
it does not mean we may directly translate the results from animal data to the human 
situation. However, this animal data could provide pre-clinical evidence for clinical 
studies on human being situation. Considering Parkinson’s disease obviously results 
in cognitive and memory impairment (Aarsland, 2008), the down-regulation of 5-
HT2A receptors in the examined mesocortical regions has important clinical 
implications, and may at least partially explain the memory impairment and stress 
dysfunction.  
                In summary, the present study examines tyrosine hydroxylase immuno- 
staining in the striatum, 5-HT2A receptor binding sites and the distributions in the rat 
brains three weeks after 6-OHDA MFB lesion. 6-OHDA lesion significantly 
decreased tyrosine hydroxylase immunostaining in the striatum, and the levels of 5-
HT2A receptor densities predominantly in the agranular insular cortex, the cingulate 
cortex, the prefrontal cortex, the primary somatosensory cortex, the caudate putamen 
compared to controls. The anatomical distributions of these alterations suggest that 
the changes of 5-HT2A receptors observed in this study among 6-OHDA PD rats have 
important clinical implications and this result may contribute, at least partially, to 
cognitive dysfunctions such as memory impairment among Parkinson’s disease 
patients via serotonin receptors. The applications of agonists or antagonist of 5-HT2A 
receptors would be a good strategy in the improvement of cognitive impairment; 
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therefore the present study implicates 5-HT2A receptors as a novel therapeutic target 
in the treatment of Parkinson’s disease.   
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Fig 1. The maps of A, B and C are adopted from a rat brain atlas (Paxinos and 
Watson, 1997) indicating the levels where the  [3H]ketanserin binding density was 
measured. Autoradiographs (D, E, F) and (D', E', F') depict the expression of  
[3H]ketanserin binding and non-specific [3H]ketanserin binding at different rostro-
caudal coronal levels of the rat brain. Abbreviations: Acb, accumbens nucleus; AI, 
agranular insular cortex; Arc, arcuate hypothalamic nucleus; Cg, cingulate cortex ; 
CPu, caudate putamen; DMH, dorsomedial hypothalamic nucleus; Ent, entorhinal 
cortex; Hip, hippocampus; M1, primary motor cortex; Me, medial amygdala; Pir, 
piriform cortex; PMCo, posteromedial cortical amygdala; PRh, perirhinal cortex; 
RSG, retrosplenial granular cortex; SNc, compact part of substantia nigra; SNr, 
reticular part of substantia nigra; Tha, thalamus; Tu, olfactory tubercle ; VDB, vertical 
limb of the diagonal band; VMH, ventromedial hypothalamus; VTA, ventral 






























Fig. 2. Typical autoradiographs depict the expression of 5-HT2A receptors in the 
cingulate cortex (Cg), caudate putamen (Cpu) and primary motor cortex (M1) 






















Fig 3. The effects of unilateral medial forebrain bundle lesion by 6-hydroxydopamine 
on [3H] ketanserin binding in the rat brain regions. Note: Units of measurement are in 
nCi/mg tissue. Data shown are the mean ± SEM. Abbreviation: S1, primary 
somatosensory cortex; PFC, prefrontal cortex. For other abbreviation see Fig 1. 
Asterisks indicate significant differences between the 6-OHDA lesioned group and 
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Fig 4. Effects of 6-OHDA lesion on TH immunohistochemistry staining in the 
caudate putamen. The right side of the photo (A) shows the dopamine-depleted 
striatum side characterized by a significant lack of TH immunoreactive fibres, while 
the left side is the intact side. Photo (B) represents the striatum in the control group, in 
which the TH immunoreactive fibres are the same as in the intact side. (C) represents 
the density of TH-positive fibres relative to the contralateral (intact) side (Student t-
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